Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.
about
Organizing principles of mammalian nonsense-mediated mRNA decayPERK Integrates Oncogenic Signaling and Cell Survival During Cancer DevelopmentTargeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.Mantle cell lymphoma activation enhances bortezomib sensitivity.Bortezomib in the management of multiple myeloma.Proteasome inhibitors in the treatment of multiple myelomaBortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphomaCleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum StressThe HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent mannerDifferential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.Endoplasmic reticulum stress in liver disease.Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS)Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myelomaTargeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.Caspase control: protagonists of cancer cell apoptosis.Efficacy of bortezomib as first-line treatment for patients with multiple myeloma.Bortezomib for the treatment of previously untreated multiple myeloma.The unfolded protein response in glioblastomas: targetable or trouble?Cariporide sensitizes leukemic cells to tumor necrosis factor related apoptosis-inducing ligand by up-regulation of death receptor 5 via endoplasmic reticulum stress-CCAAT/enhancer binding protein homologous protein dependent mechanism.DNA damage response-initiated cytokine secretion in bone marrow stromal cells promotes chemoresistance of myeloma cells.Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.The unfolded protein response in glioblastomas: passing the stress test.
P2860
Q28302705-7CA8AF8A-7386-42EC-A810-91591CA346A7Q28397172-7A761BE5-18F8-4513-B58B-85A4B3538DA2Q33585280-AA5F50C5-ADD0-4B8C-B3D2-520B7C80E3CFQ34360347-B78BBA2D-F4EC-47A1-BAE6-5D11ED10F1ABQ34418462-02DD29EA-447C-4595-A853-584D6D8BE7B7Q34611676-94E5948A-7187-4E68-86ED-51AC32A35897Q35067397-CF0CF7BB-4018-40AF-B535-BDC62388CDAAQ35266125-4C4921FE-B033-451B-81D1-7057FFD2D544Q35475256-BD527CDD-EFD4-4C27-BCCD-199FA242FB10Q35626096-2A4B8731-58EF-4C0A-B376-25F9C70B90C7Q35779961-21441CCC-935F-4E94-A928-04916AACF094Q35974731-DD511383-BE64-4BA6-8E9D-66EF95D6E270Q36031838-3AB60521-F6CD-4211-A6FC-7A2657629A0AQ36342992-E77E7C22-6B1F-466D-8D06-BC918C45CE6AQ37031914-9F289F82-689B-4EDA-894B-F395EC7A8DB9Q37327294-A66F0166-8843-42A0-A178-D9C7BEA6BE12Q37827173-EC604804-9405-4CAF-BFB5-58B428D8B338Q38052382-AC71AD27-C2F5-4234-9EF3-5A0E8A50A2BAQ38089497-442AA8E1-AEC8-444D-BF97-7DB9DE393260Q38096055-F9B088AE-1B55-4914-A35D-D3CB719AD2B7Q38970037-A8A9D5A8-0359-4BF4-8ECD-56C1A2CE6DB3Q39067333-68EBA677-44F3-4AE8-AAC1-D369F6418761Q47242309-C85DCBE9-4A77-4882-A29B-C44F2382B8A5Q47253158-EB7916E0-2E6C-4E88-89D6-8348C3392FC7Q48641880-91A9FC3F-C6F7-451C-912F-DB6E6DB3066A
P2860
Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Dysregulation of unfolded prot ...... mib in multiple myeloma cells.
@ast
Dysregulation of unfolded prot ...... mib in multiple myeloma cells.
@en
Dysregulation of unfolded prot ...... mib in multiple myeloma cells.
@nl
type
label
Dysregulation of unfolded prot ...... mib in multiple myeloma cells.
@ast
Dysregulation of unfolded prot ...... mib in multiple myeloma cells.
@en
Dysregulation of unfolded prot ...... mib in multiple myeloma cells.
@nl
prefLabel
Dysregulation of unfolded prot ...... mib in multiple myeloma cells.
@ast
Dysregulation of unfolded prot ...... mib in multiple myeloma cells.
@en
Dysregulation of unfolded prot ...... mib in multiple myeloma cells.
@nl
P2093
P2860
P1433
P1476
Dysregulation of unfolded prot ...... mib in multiple myeloma cells.
@en
P2093
Baoxia Dong
Guangxun Gao
Hongjuan Dong
Hongtao Gu
Liang Chen
Xiequn Chen
P2860
P304
P356
10.1080/10428190902895780
P577
2009-06-01T00:00:00Z